NCT00000392

Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 215 (actual)
• Sponsor: National Institute of Mental Health (NIMH) · NIH
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.

Conditions

• HIV Infections
• Cognition Disorders

Interventions

Type	Name	Description
DRUG	Peptide T
DRUG	Placebo

Timeline

• Start date: 1990-01-01
• Primary completion: 1996-08-01
• Completion: 1996-08-01
• First posted: 2000-01-18
• Last updated: 2017-02-28
• Results posted: 2015-08-04

Locations

3 sites across 1 country: United States